Cover Image
市場調查報告書

肥大性心肌病:主要8個國家的市場預測

Hypertrophic Cardiomyopathy Forecast in 8 Major Markets 2015-2025

出版商 Black Swan Analysis 商品編碼 339843
出版日期 內容資訊 英文 38 Pages
訂單完成後即時交付
價格
Back to Top
肥大性心肌病:主要8個國家的市場預測 Hypertrophic Cardiomyopathy Forecast in 8 Major Markets 2015-2025
出版日期: 2015年08月01日 內容資訊: 英文 38 Pages
簡介

肥大性心肌病 (HCM) ,由於有平常染色體優勢形式的遺傳模式的疾病,遺傳性的趨勢「稍稍」存在。主要的特徵是左心室的肥大化,其原因在其他疾病 (高血壓等) 的存在無法說明等。

本報告提供全球主要8個國家(美國、法國、德國、義大利、西班牙、英國、巴西、日本) 的肥大性心肌病 (HCM) 的發病情形相關分析、疾病概要和目前的患病人數、性別、各年代 (5歲區分) 的詳細情況、各地區/各民族趨勢、風險要素、疾病診斷與預後、主要的症狀和併發症、未來性的趨勢預測 (今後10年份) 的資訊彙整為您概述為以下內容。

概要

簡介

疾病的原因

風險要素與預防法

疾病診斷

各地區/各民族的差異

疾病的預後與臨床過程

疾病相關的主要共生病症/特徵

患者數的定量化技術

肥大性心肌病的最大患病人數

肥大性心肌病 (HCM) 的主要類型和心臟相關的特徵

  • HCM的主要類型
  • HCM的各症狀的明細
  • HCM的心臟相關的特徵
  • HCM相關的死亡者數

HCM相關的重大併發症

HCM相關的遺傳基因突變

參考文獻

附錄

圖表一覽

目錄
Product Code: HYPC0010815

Hypertrophic cardiomyopathy (HCM) is a disease that contains an autosomal dominant inheritance pattern and is a moderately common "transmitted" genetic disease. The disease, characterized by hypertrophy in the left ventricle, cannot be explained by the presence of other clinical symptoms, such as hypertension. This report provides the current prevalent population for HCM across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the types, occlusion locations and the prevalence of associated disorders of HCM. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of HCM have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for HCM include:

  • Chronic heart failure
  • Angina pectoris
  • Atrial fibrillation
  • Tachycardia

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global HCM's market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of HCM and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on HCM's prevalent population.
  • Examination of the prevalence of the different causative gene mutations for HCM.
  • Identify sub-populations within HCM which require treatment.
  • Gain an understanding of the specific markets that have the largest number of HCM patients.

Coverage

US, UK, FR, DE, IT, ES, JP, BR

Table of Contents

List of Tables & Figures

Overview

Introduction

Cause of the Disease

Risk Factors & Prevention

Diagnosis of the Disease

Variation by Geography/Ethnicity

Disease Prognosis & Clinical Course

Key Co-morbid Conditions/Features Associated with the Disease

Methodology for Quantification of Patient Numbers

Top-Line Prevalence for Hypertrophic Cardiomyopathy

Main Type and Cardiac Features of Hypertrophic Cardiomyopathy

  • HCM main type
  • HCM by symptoms
  • Cardiac features of HCM
  • HCM related death

Significant Co-morbid Conditions Associated with HCM

Gene Mutations within HCM

References

Appendix

List of Tables & Figures

  • Prevalence of HCM, total (000s)
  • Prevalence of HCM, males (000s)
  • Prevalence of HCM, females (000s)
  • HCM by main type - familial vs. sporadic, total (000s)
  • Symptomatic HCM, total (000s)
  • Dyspnoea within symptomatic HCM (000s)
  • Clinical heart failure within symptomatic HCM (000s)
  • Angina pectoris within symptomatic HCM (000s)
  • Syncope within symptomatic HCM (000s)
  • Paroxysmal supraventricular tachycardia within symptomatic HCM (000s)
  • Dynamic Left Ventricular Outflow obstruction (LVOT) in patients with HCM, total (000s)
  • Maximum Left Ventricular Thickness (LVT) in patients with HCM, total (000s)
  • Causes of death associated with HCM, total (000s)
  • Prevalence of hypertension in patients with HCM, total (000s)
  • Prevalence of atrial fibrillation in patients with HCM, total (000s)
  • Key gene mutation within HCM patients, total (000s)
  • USA Prevalence of HCM by 5-yr age cohort, males (000s)
  • USA Prevalence of HCM by 5-yr age cohort, females (000s)
  • France Prevalence of HCM by 5-yr age cohort, males (000s)
  • France Prevalence of HCM by 5-yr age cohort, females (000s)
  • Germany Prevalence of HCM by 5-yr age cohort, males (000s)
  • Germany Prevalence of HCM by 5-yr age cohort, females (000s)
  • Italy Prevalence of HCM by 5-yr age cohort, males (000s)
  • Italy Prevalence of HCM by 5-yr age cohort, females (000s)
  • Spain Prevalence of HCM by 5-yr age cohort, males (000s)
  • Spain Prevalence of HCM by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of HCM by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of HCM by 5-yr age cohort, females (000s)
  • Brazil Prevalence of HCM by 5-yr age cohort, males (000s)
  • Brazil Prevalence of HCM by 5-yr age cohort, females (000s)
  • Japan Prevalence of HCM by 5-yr age cohort, males (000s)
  • Japan Prevalence of HCM by 5-yr age cohort, females (000s)
Back to Top